Recurrent Melanoma Terminated Phase 2 Trials for Temsirolimus (DB06287)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01166126Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IVTreatment